Ralliant Corp.

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
4.0

Key Drivers

  • Strong gross margin
  • Positive free cashflow
  • Liquidity stressed

AI
AI Summary

4.0

RAL's investment case has shifted to a governance- and balance-sheet-driven risk profile—where a $1.4B goodwill impairment, activist/legal overhang and constrained liquidity make near-term upside contingent on demonstrable multi-quarter EBITDA/FCF recovery and decisive deleveraging or asset sales.

FreeCashFlow
Governance
Reorg‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong gross margin
  • Positive free cashflow
  • Liquidity stressed

RAL exhibits strong gross margins and positive free cash flow but suffers severe operating losses, negative profitability, strained short-term liquidity, and high leverage.

FreeCashFlow
Leverage

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Lower lows
  • Defined range

Over the last month to 2026-03-20 RAL is in a short-term downtrend (~6–7% decline) with lower highs/lows, key support near $40.80–$42.10 and resistance near $46.30–$47.00, where a break below support raises downside risk and a break above resistance would be a clear bullish signal—verify news/volume due to a large Feb gap (56.22→38.35) that distorts technicals.

bearish
rangebound
Support Level: $40.80–$42.10
Resistance Level: $46.30–$47.00

Large gap from $56.22 to $38.35 in early

Sentiment & News

7.0

Key News Insights:

  • Large goodwill hit
  • Investor lawsuits
  • Activist pressure

Ralliant's $1.4B goodwill impairment and sharply reduced 2026 guidance sparked 15–30% share declines, multiple investigations, activist pressure for cuts/buybacks, and negative analyst sentiment.

Goodwill

The impairment and ensuing legal/activist scrutiny materially raise near‑term downside risk and should pressure management into swift cost reductions or share‑repurchase actions